BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9817282)

  • 1. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response.
    Gandhi V; Plunkett W; Rodriguez CO; Nowak BJ; Du M; Ayres M; Kisor DF; Mitchell BS; Kurtzberg J; Keating MJ
    J Clin Oncol; 1998 Nov; 16(11):3607-15. PubMed ID: 9817282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells.
    Gandhi V; Plunkett W; Weller S; Du M; Ayres M; Rodriguez CO; Ramakrishna P; Rosner GL; Hodge JP; O'Brien S; Keating MJ
    J Clin Oncol; 2001 Apr; 19(8):2142-52. PubMed ID: 11304766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature.
    Aguayo A; Cortes JE; Kantarjian HM; Beran M; Gandhi V; Plunkett W; Kurtzberg J; Keating MJ
    Cancer; 1999 Jan; 85(1):58-64. PubMed ID: 9921974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of nelarabine in indolent leukemias.
    Gandhi V; Tam C; O'Brien S; Jewell RC; Rodriguez CO; Lerner S; Plunkett W; Keating MJ
    J Clin Oncol; 2008 Mar; 26(7):1098-105. PubMed ID: 18309944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells.
    Yamauchi T; Nishi R; Kitazumi K; Nakano T; Ueda T
    Oncol Rep; 2010 Feb; 23(2):499-504. PubMed ID: 20043113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies.
    Lambe CU; Averett DR; Paff MT; Reardon JE; Wilson JG; Krenitsky TA
    Cancer Res; 1995 Aug; 55(15):3352-6. PubMed ID: 7614470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies.
    Kisor DF; Plunkett W; Kurtzberg J; Mitchell B; Hodge JP; Ernst T; Keating MJ; Gandhi V
    J Clin Oncol; 2000 Mar; 18(5):995-1003. PubMed ID: 10694549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells.
    Rodriguez CO; Legha JK; Estey E; Keating MJ; Gandhi V
    Clin Cancer Res; 1997 Nov; 3(11):2107-13. PubMed ID: 9815603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias.
    Kisor DF
    Ann Pharmacother; 2005 Jun; 39(6):1056-63. PubMed ID: 15870141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nelarabine: a novel purine antimetabolite antineoplastic agent.
    Buie LW; Epstein SS; Lindley CM
    Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.
    Kadia TM; Gandhi V
    Expert Rev Hematol; 2017 Jan; 10(1):1-8. PubMed ID: 27869523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step.
    Rodriguez CO; Gandhi V
    Cancer Res; 1999 Oct; 59(19):4937-43. PubMed ID: 10519407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nelarabine in the treatment of refractory T-cell malignant diseases.
    Kline J; Larson RA
    Expert Opin Pharmacother; 2006 Sep; 7(13):1791-9. PubMed ID: 16925505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies.
    Kurtzberg J; Ernst TJ; Keating MJ; Gandhi V; Hodge JP; Kisor DF; Lager JJ; Stephens C; Levin J; Krenitsky T; Elion G; Mitchell BS
    J Clin Oncol; 2005 May; 23(15):3396-403. PubMed ID: 15908652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts.
    Verhoef V; Fridland A
    Cancer Res; 1985 Aug; 45(8):3646-50. PubMed ID: 2410098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL.
    Horibe K; Takimoto T; Yokozawa T; Makimoto A; Kobayashi Y; Ogawa C; Ohno R; Koh N; Katsura K; Tobinai K
    Rinsho Ketsueki; 2011 Jun; 52(6):406-15. PubMed ID: 21737993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine.
    Rodriguez CO; Stellrecht CM; Gandhi V
    Blood; 2003 Sep; 102(5):1842-8. PubMed ID: 12750168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nelarabine: a new purine analog in the treatment of hematologic malignancies.
    Curbo S; Karlsson A
    Rev Recent Clin Trials; 2006 Sep; 1(3):185-92. PubMed ID: 18473971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase.
    Rodriguez CO; Mitchell BS; Ayres M; Eriksson S; Gandhi V
    Cancer Res; 2002 Jun; 62(11):3100-5. PubMed ID: 12036920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
    Kantarjian HM; Gandhi V; Kozuch P; Faderl S; Giles F; Cortes J; O'Brien S; Ibrahim N; Khuri F; Du M; Rios MB; Jeha S; McLaughlin P; Plunkett W; Keating M
    J Clin Oncol; 2003 Mar; 21(6):1167-73. PubMed ID: 12637486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.